Testing and Linkage to Care for Injecting Drug Users in Kenya

NACompletedINTERVENTIONAL
Enrollment

9,449

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2018

Conditions
HIV InfectionHCV Coinfection
Interventions
BEHAVIORAL

POC CD4 and Peer Case Management

HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.

DRUG

HCV+PWID

Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.

BEHAVIORAL

Control - No intervention

Trial Locations (1)

Unknown

National AIDS/STD Control Programme (NASCOP), Nairobi

All Listed Sponsors
collaborator

NYU Langone Health

OTHER

collaborator

Kenya National AIDS & STI Control Programme

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT01557998 - Testing and Linkage to Care for Injecting Drug Users in Kenya | Biotech Hunter | Biotech Hunter